At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,530 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Obicetrapib 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
In Brief
A Phase 3 clinical trial evaluating Placebo and Obicetrapib for Dyslipidemias and 4 related conditions. Completed, enrolled 2,530 participants across 181 sites in 8 countries.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
CountriesChina, Czechia, Denmark, Georgia, Japan, Netherlands, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartDec 2021
Primary CompletionSep 2024
TodayJul 2026
First PostedDec 3, 2021
Enrollment StartDec 15, 2021
Primary CompletionSep 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.6 years ago
Interventions
Placebodrug
placebo tablet made to resemble active
Obicetrapibdrug
10mg obicetrapib tablet